Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Renal Cell 7Kidney Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Neoplasm Metastasis 2Clear-cell metastatic renal cell carcinoma 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Cystadenocarcinoma, Serous 1Colorectal Neoplasms 1Carcinosarcoma 1Carcinoma 1Breast Neoplasms 1Advanced Renal Cell Carcinoma (RCC) 1Adenocarcinoma, Mucinous 1

Interventions

Trastuzumab 62Paclitaxel 57Cyclophosphamide 44pembrolizumab 34Fulvestrant 34Capecitabine 29Carboplatin 26Docetaxel 23Letrozole 22Doxorubicin 19palbociclib 16abemaciclib 16pertuzumab 15durvalumab 14Filgrastim 13Everolimus 13ribociclib 12Lapatinib 12Gemcitabine 12exemestane 11eribulin 11Vinorelbine 11Albumin-Bound Paclitaxel 11Bevacizumab 10trastuzumab deruxtecan 9neratinib 9fludarabine 9Taxes 9Radiotherapy 9Peripheral Blood Stem Cell Transplantation 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Breast Neoplasms × Axitinib × Clear all
NCT00076024 2012-06-26

AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer

Pfizer

Phase 1/2 Completed
174 enrolled 14 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡